Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.

Subjects

Subjects :

Australia
Biological Therapy trends
Humans
Inflammatory Bowel Diseases drug therapy
Mesalamine administration & dosage
Biological Therapy economics
Inflammatory Bowel Diseases economics
Mesalamine economics

Details

Language :

English

ISSN :

1878-3562

Volume :

50

Issue :

3

Database :

MEDLINE

Journal :

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Publication Type :

Editorial & Opinion

Accession number :

29311026

Full Text :

https://doi.org/10.1016/j.dld.2017.12.016